KPV, GHK-Cu, BPC-157 and TB-500 (KLOW stack)
What does KPV add to the GLOW stack, and when is the KLOW stack worth the fourth peptide?
Reviewed by the amino101 editorial team. .
Also searched as KLOW protocol, KLOW peptide blend, KPV GLOW stack, GLOW plus KPV.
KPV is a three amino acid fragment of alpha-melanocyte stimulating hormone that carries the anti-inflammatory effect of the hormone without its pigmentation effect. It is used for inflammatory bowel symptoms, skin inflammation and general inflammation control.
GHK-Cu is a naturally occurring tripeptide bound to copper that declines with age. It is used topically for skin firmness, wrinkles and hair growth, and by injection for wound healing, skin remodeling and general tissue repair.
BPC-157 is a 15 amino acid fragment of a protective protein found in human gastric juice. People use it for tendon, ligament, muscle and gut healing, and it is one of the most widely used research peptides in the recovery space.
TB-500 is a synthetic version of the active region of thymosin beta-4, a protein found in nearly every human cell that regulates actin and cell movement. It is used for injury recovery, flexibility and general tissue repair, usually alongside BPC-157.
KLOW is the GLOW stack with KPV added, and the name is a forum play on GLOW rather than a product. People add KPV because the other three are repair peptides and none of them directly turns down inflammation. KPV is the last three amino acids of alpha-MSH, it blocks NF-kB signaling, the switch for inflammatory gene expression, and it does so without the tanning effect of the parent hormone. The evidence for KPV is mouse colitis and skin inflammation models plus cell work. There are no human trials of KPV at all, and the four compounds have never been studied together. The rest of the stack carries the same caveats as GLOW: topical GHK-Cu has human trials, injectable does not, and BPC-157 and TB-500 rest on rodent and veterinary data.
The honest summary is that KLOW is a four compound protocol built from one compound with human skin data and three with none. It gets searched because vendors sell it as a blend and because people with gut problems, eczema or lingering post-infection inflammation want a reason to run it over GLOW. This page explains what KPV adds, when it is pointless, and how the dosage and mixing work. It is educational, not a protocol anyone is prescribing; all four are unapproved for this use.
Why people combine KPV, GHK-Cu, BPC-157 and TB-500
BPC-157, TB-500 and GHK-Cu all have some anti-inflammatory activity as a side effect of promoting repair, but none of them targets NF-kB directly. KPV does, lowering TNF-alpha, IL-6 and IL-1 beta in cell and mouse studies. For someone whose problem is driven by inflammation rather than a mechanical injury, that is the gap KLOW fills.
KPV is carried into inflamed intestinal cells by the PepT1 transporter, which is upregulated during inflammation, and oral KPV reduced colitis in several mouse models. BPC-157 has the deepest rodent literature of anything on this site for gut lining protection. Together they are the gut half of KLOW, and for a gut-first problem the BPC-157 and KPV pair alone is usually enough.
GHK-Cu remodels collagen. KPV calmed ear swelling and dermatitis in mouse models and has in vitro activity against Staphylococcus aureus and Candida. For eczema-prone skin healing after a procedure, that pairing has a logic the GLOW stack on its own does not.
A clean tendon injury, a scar with no redness, or post-surgical recovery in someone with no inflammatory condition. In those cases KPV is a fourth injection or capsule that suppresses a process the other three are already managing fine. There is also a theoretical cost: broad NF-kB suppression could blunt a needed immune response, and the KPV compound page notes most people pause it when sick.
KLOW stack dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| KPV | 250 to 500 mcg injectable or nasal; 500 mcg to 1 mg oral | once or twice daily | subcutaneous in the abdomen, or an oral capsule on an empty stomach for gut complaints |
| GHK-Cu | 1 to 2 mg | once daily | subcutaneous in the abdomen or thigh, separate syringe, often in the evening |
| BPC-157 | 250 to 500 mcg | once or twice daily | subcutaneous near the injury or in the abdomen; oral capsule for gut use |
| TB-500 | 2 to 2.5 mg | twice weekly for 4 to 6 weeks | subcutaneous in the abdomen, any time |
4 to 8 weeks, the same as GLOW and the same as each compound alone. KPV is often the first thing dropped: some people run it only for the first 2 to 4 weeks while inflammation is highest, or only around flares. A 2 to 4 week break follows, and the only way to know whether KPV was doing anything is to leave it out of the next run and see whether symptoms return.
- •For a gut-focused run, KPV and BPC-157 are both taken orally on an empty stomach, 30 minutes or more before food, and GHK-Cu and TB-500 stay injectable.
- •Most people start KPV at 250 mcg to check tolerance; nausea and headache are the usual complaints with injectable KPV.
- •GHK-Cu stings. Diluting to 2 mg per mL or lower and rotating sites helps, and it stays in its own syringe.
- •Most people pause KPV during an active infection. Suppressing NF-kB broadly is not what you want while fighting something off.
Work out syringe units for any of these in the dosage calculator.
Can you mix KPV, GHK-Cu, BPC-157 and TB-500 in one syringe?
KPV has no known conflict with BPC-157 or TB-500 and the three are sometimes drawn together, though no stability data exists for any peptide mixture sold on the research market. The GHK-Cu debate applies here exactly as it does to GLOW: its copper ion and pH around 5 to 6.5 may degrade the other peptides in a shared vial, so the compound pages say inject it separately, while vendors sell pre-mixed KLOW blends and users report them working. The safest reading of both sides is one syringe for GHK-Cu and one for everything else. For gut protocols the question mostly goes away, since KPV and BPC-157 are taken as capsules; see oral vs injectable BPC-157.
What to expect, week by week
- Week 1 to 2
Gut users often report less bloating, urgency or discomfort from KPV and BPC-157. Skin users notice less itching and redness. GHK-Cu stinging and bruising are at their worst.
- Week 3 to 4
If KPV is going to help, its effect is usually clear by now as a steady drop in background inflammation. Scars look flatter and soft tissue range of motion improves.
- Week 5 to 8
KPV gains plateau and many people stop it here. GHK-Cu skin texture changes start, and the TB-500 loading phase ends.
- Beyond week 8
Skin firmness changes continue on the 12 week topical trial timeline. Gut symptoms that return after stopping are the clearest sign KPV was doing something.
Side effects and cautions
- ▲Nausea, mostly from injectable KPV and from oral BPC-157 capsules
- ▲Headache, reported with all four compounds
- ▲Injection site stinging, redness and bruising from GHK-Cu
- ▲Stomach upset from oral KPV capsules
- ▲Fatigue, from KPV in a minority of users and from larger TB-500 doses
- ▲Metallic taste or brief nausea after a GHK-Cu injection
- ▲More injection site irritation simply from the number of injections per day
- ■Anyone on immunosuppressants, TNF blockers or other biologics. Adding KPV on top has never been studied and could blunt immune responses further; it needs the prescriber's input.
- ■An active infection. KPV is usually paused, and three other injections into irritated skin is a poor idea anyway.
- ■Wilson disease or copper metabolism disorders, because of GHK-Cu, and active or recent cancer, because of all four.
- ■Undiagnosed gut symptoms. Blood in stool, weight loss or persistent pain needs a diagnosis before anyone suppresses the inflammation that would point to it.
KLOW is a reasonable stack for a narrow group: people recovering from a procedure or injury who also have an inflammatory problem running in the background, such as inflammatory bowel symptoms, eczema or an inflamed, slow-healing wound. KPV is the only one of the four that targets inflammation directly, and in that setting it earns its place. For everyone else it is GLOW with an extra compound. A clean tendon injury is a Wolverine stack job. A scar or post-laser skin is GLOW. A gut problem on its own is BPC-157 and KPV, which skips the copper peptide and the TB-500 and costs a fraction as much. Four compounds also means four sets of side effects and no way to tell which one did what, so anyone who has not run the components separately first is guessing. All four are unapproved, KPV has never been in a human trial, and this is educational background rather than a protocol.
KLOW stack: frequently asked
What is the difference between KLOW and GLOW?
One peptide. KLOW is GLOW plus KPV, a three amino acid anti-inflammatory fragment of alpha-MSH. GLOW covers tissue repair, cell migration and collagen remodeling. KPV adds direct suppression of NF-kB driven inflammation, which matters for gut and inflammatory skin problems and not much otherwise.
Is the KLOW stack better than GLOW?
Not by default. If your problem has an inflammatory driver, like colitis-type symptoms, eczema or lingering post-infection inflammation, KPV is the one addition that targets it. If your problem is a scar, a tendon or post-surgical recovery in someone otherwise well, GLOW already covers it and KPV is dead weight.
Can KPV be taken orally in the KLOW stack?
Yes, and for gut complaints oral is the usual route, 500 mcg to 1 mg on an empty stomach. The mouse colitis data used protective nanoparticle formulations that most vendors do not sell, so plain capsules may lose some peptide to digestion. BPC-157 can go oral at the same time; GHK-Cu and TB-500 stay injectable.
Does KPV cause tanning like melanotan?
No. KPV is the fragment of alpha-MSH that does not bind the pigment receptor. It was isolated precisely because it keeps the anti-inflammatory effect and drops the tanning. Melanotan is a different compound.
What is the KLOW stack dosage?
Reported protocols use KPV at 250 to 500 mcg injectable or 500 mcg to 1 mg oral once or twice daily, GHK-Cu 1 to 2 mg daily, BPC-157 250 to 500 mcg once or twice daily and TB-500 2 to 2.5 mg twice weekly. None of the doses change because the compounds are stacked. The peptide dosage chart has all four side by side.
How long should you run KLOW?
4 to 8 weeks for the full stack. KPV is often run shorter, for the first few weeks or around flares, because it has no long term human safety data of any kind. Then a break of 2 to 4 weeks, leaving KPV out of the next run to see whether it mattered.
Related reading
Skin, scar and post-procedure healing
Gut lining repair and inflammation control
Soft tissue and tendon injury recovery
Both are gut peptides. One repairs, one calms inflammation. Which problem do you have?
Which healing peptide should you start with, and do you need both?
Guide
Dosage
Safety
Same first name, nothing else in common. Which thymosin do you actually want?
Sources
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011